Format

Send to

Choose Destination
Am J Psychiatry. 1995 Aug;152(8):1213-5.

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

Author information

1
Erich Lindemann Mental Health Center, Department of Psychiatry, Massachusetts General Hospital, Boston.

Abstract

OBJECTIVE:

The authors conducted a dose-finding study of D-cycloserine, a partial agonist at the glycine site of the N-methyl-D-aspartate subtype of the glutamate receptor, added to conventional neuroleptics for schizophrenic patients with prominent negative symptoms.

METHOD:

Nine patients with schizophrenia completed consecutive 2-week trials of placebo and four doses of D-cycloserine. Clinical assessments were videotaped and were scored by a rater who was blind to temporal sequence.

RESULTS:

D-Cycloserine at a dose of 50 mg/day produced a significant reduction (mean = 21%, SD = 28%) in negative symptoms and significantly improved reaction time as measured by Sternberg's Item Recognition Paradigm, a test mediated in part by prefrontal cortex.

CONCLUSIONS:

This preliminary evidence suggests that D-cycloserine may improve negative symptoms and cognitive deficits over a narrow dose range when added to conventional antipsychotic agents.

PMID:
7625475
DOI:
10.1176/ajp.152.8.1213
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center